DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DexCom, Inc. (DXCM) has a planned sale of 2,000 shares of common stock through UBS Financial Services, Inc., with an aggregate market value of $160,000.00, listed on NASDAQ and expected on July 31, 2026. The shares originate from vested RSUs granted in 2019 and 2026. A related holder, The Foletta Family Trust dtd 1/30/2015, previously sold 4,000 common shares on June 15, 2026 for $296,539.60.
DexCom generated strong results for the quarter ended June 30, 2026, with revenue of $1,308.4 million, up 13% year over year, and gross profit of $830.0 million, raising gross margin to 63.4% from 59.5%. Operating income rose to $318.3 million (up 50%), and net income to $249.1 million (up 39%), or $0.64 diluted EPS, driven mainly by higher disposable sensor volumes, continued expansion of the worldwide customer base, and favorable revenue per customer, partly offset by channel/product mix, rebate eligibility, and higher inventory reserves tied to the planned discontinuation of G6 manufacturing.
For the first six months of 2026, revenue reached $2,500.3 million (up 14%) and net income $448.6 million (up 57%), as G7 15 Day benefits, improved manufacturing efficiencies, higher production volumes and a more favorable manufacturing mix lifted margins despite larger excess and obsolete inventory charges of $84.2 million. Operating cash flow was $794.8 million, and DexCom ended the period with $1.95 billion in cash, cash equivalents and short-term marketable securities. Capital allocation included repurchasing 8.6 million shares for $600.0 million under the 2026 Share Repurchase Program, while maintaining $1.25 billion of 0.375% senior convertible notes due 2028 and an undrawn $200.0 million revolving credit facility (aside from $8.7 million in letters of credit).
Dexcom reported financial results for the quarter ended June 30, 2026. Revenue grew 13% year-over-year to $1.308 billion, with U.S. revenue up 11% and international revenue up 19%. GAAP gross margin was 63.4% and non-GAAP gross margin 64.1%. GAAP operating income was $318.3 million, a 24.3% margin, while non-GAAP operating income was $328.3 million, or 25.1% of revenue. GAAP net income was $249.1 million, or $0.64 per diluted share, and non-GAAP net income was $269.1 million, or $0.70 per diluted share. Adjusted EBITDA was $421.3 million.
Strategic updates included a 2026 Investor Day, positive CONNECT trial results in type 2 diabetes patients not using insulin, and the launch of a redesigned Stelo app with AI-driven insights. Dexcom raised the midpoint of 2026 revenue guidance to $5.18–$5.25 billion and increased targets for Non-GAAP Gross Profit Margin to about 64%, Non-GAAP Operating Margin to 23.5–24%, and Adjusted EBITDA Margin to 31.5–32%. As of June 30, 2026, Dexcom held $1.95 billion in cash, cash equivalents and marketable securities, with its revolving credit facility undrawn.
Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62. The sale was made under a Rule 10b5-1 trading plan adopted on February 18, 2026 for orderly dispositions of his holdings. Following this sale, he directly holds 328,970 shares, including 106,972 unvested restricted stock units that were granted in 2024–2026 and will vest through 2028.
Dexcom, Inc. (DXCM) has a planned sale of common stock reported by affiliate Kevin R. Sayer. The notice covers up to 26,756 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $2,041,999.19 as of the filing.
The shares derive from performance and restricted stock awarded on March 8, 2021. Dexcom reports 385,872,977 common shares outstanding, a baseline figure, not the amount being sold. In the past three months, Sayer sold 26,756 shares on July 6, 2026 for $1,926,432.00 and 26,759 shares on May 21, 2026 for $1,926,648.00.
DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of Dexcom common stock on July 15, 2026 at an average price of $74.42 per share, executed under a 10b5-1 plan adopted on November 26, 2025. Following this transaction, he holds 104,653 shares in total, including 74,753 unvested restricted stock units scheduled to vest in several grants through March 8, 2029.
Michael Brown plans to sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or about July 15, 2026, with an aggregate market value of $126,514.00.
There are 385,872,977 common shares outstanding. Over the past three months, Brown sold 1,700 shares on May 15, 2026 for $101,847.00 and 1,700 shares on June 15, 2026 for $128,435.00.
Dexcom Inc. Executive Chair Kevin R. Sayer sold 26,756 shares of common stock in an open-market transaction at $72.00 per share. The sale was executed under a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026 to allow orderly dispositions of his holdings.
After the transaction, Sayer directly owns 355,726 Dexcom shares, which include 106,972 unvested restricted stock units scheduled to vest in tranches through March 8, 2028. The filing shows he retains a substantial equity position following this planned sale.
DexCom filed a Form 144 reporting a proposed sale of 26,756 shares of Common stock. The filing shows an associated value of $1,926,432.00 and names Kevin R. Sayer in the transaction details. The filing lists 07/06/2026 and indicates placement with Morgan Stanley Smith Barney LLC.
DexCom Inc. executive Michael Jon Brown, EVP and Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of common stock at $75.55 per share on June 15, 2026. After the sale, he directly holds 106,353 shares, including 74,753 unvested restricted stock units that vest over multiple dates through March 8, 2029. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance as part of an orderly disposition program.